DMD.
Company
- Reports this week
- 0
- Active events
- 1
- Connections
- 51
What's happening
Active this week
Earlier this month
One to three months ago
Gone quiet
No new reports in 90+ days-
DMD serves customers across the North America region.Some support1 report
-
Sarepta Therapeutics, which develops precision genetic medicines for DMD, trades on the Nasdaq and is headquartered in Cambridge.Well supported4 reports
-
The FDA accepted the Biologics License Application (BLA) for a DMD therapy developed by a company led by John Cox.Some support1 report
-
DMD develops therapeutics targeting muscle tissue through strategic collaborations involving Roche, Recursion, and Dyne Therapeutics.Some support1 report
-
Director Jason Rhodes sold company stock of DMD, with the transaction disclosed in an SEC filing.Some support5 reports
-
Nippon Shinyaku is funding the development of treatments for DMD, with its US subsidiary located in New Jersey.Some support1 report
-
DMD sponsors a fair dedicated to raising awareness about research in the field.Some support1 report
-
Cumberland Pharmaceuticals is advancing clinical trials for DMD treatments in the US and internationally.Some support2 reports1 development inside
-
Dyne announced the development of therapies for DMD and myotonic dystrophy type 1, with John Cox serving as CEO.Some support3 reports1 development inside
-
Sarepta Therapeutics is developing gene therapies for DMD. The FDA has mandated a black box warning for ALF due to patient deaths linked to the compound in trials.Some support1 report
-
FDA granted breakthrough therapy designation to Avidity Biosciences for a drug candidate targeting DMD.Some support2 reports
-
Wave Life Sciences delivered positive data from the N531 trial, with future milestones and payments remaining uncertain.Some support2 reports
-
Cumberland Pharmaceuticals' product Vibativ received regulatory approval in China.Some support1 report
-
The FDA granted Orphan Drug Designation for KER-065, a therapeutic being developed by KROS for DMD.Some support1 report
-
Wave Life Sciences, based in Singapore, is developing therapies for DMD and targeting Huntington’s disease.Some support1 report
No events began in the chosen period. Widen it, or reset.
Explainers that pass through DMD
DMD is a step on the way to someone elseAround DMD this week
News at the entities that move DMD most-
city council StructuralSturgis City Council approved a fee increase for ambulance services on November 11, 2026.Moves DMD
-
Food and Drug Administration StructuralSeaStar Medical submitted a premarket approval application to the FDA and discussed trial enrollment plans.Moves DMD
-
SEC StructuralContinuum Advisory LLC bought a stake in the Unusual Whales Subversive Democratic Trading ETF and filed Form 13F with the SEC.Moves DMD
-
FDA StructuralFDA approval coincided with Donald Trump's press conference on November 11, 2026.Moves DMD
-
Bihar Shared contextNitish Kumar formed a government with the BJP in Bihar, prompting political responses from Sonia Gandhi and Digvijaya Singh.Moves DMD
-
Sarepta Therapeutics OperationalMarketBeat reported analyst ratings for Sarepta Therapeutics and Emergent BioSolutions, both of which are listed on Nasdaq.Moves DMD
Connections
The 20 strongest of 51, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Food and Drug Administration Structural
DMD's therapies are subject to formal regulation by the FDA, including receiving designations and BLA acceptance.
-
Sarepta Therapeutics Operational
Sarepta Therapeutics actively develops and focuses on treatments for Duchenne muscular dystrophy.
-
Armscor Structural
DMD tasks Armscor to execute acquisitions and provide support functions.
-
Dyn Structural
Dyn is actively developing therapeutic treatments targeting DMD.
-
Jennifer Turner Structural
Jennifer Turner holds the formal role of Director at DMD.
-
city council Structural
The city council structurally regulates DMD through ordinances that direct the company's priorities and actions.
-
John Cox Structural
John Cox holds a leadership role within DMD, which is focused on developing treatments for DMD.
-
SEC Structural
DMD is subject to regulatory oversight by the SEC, as evidenced by SEC filings.
Show all 20 connections
-
FDA Structural
The FDA structurally regulates DMD, making decisions and granting designations critical to the company's operations.
-
Capricor Therapeutics (United States) Operational
Capricor Therapeutics is actively developing and seeking approval for therapies targeting Duchenne Muscular Dystrophy.
-
Nippon Shinyaku Structural
Nippon Shinyaku is funding the development of treatments for DMD.
-
Fairbury Transactional
DMD provides financial sponsorship to Fairbury to promote research awareness.
-
Bihar Shared context
DMD operates within the geographical context of Bihar, primarily managing and reporting on flood response efforts.
-
North America Shared context
The company operates within the geographic and economic context of North America, serving customers across the region.
-
Peking Union Medical College Hospital Operational
The hospital conducts clinical trials for patients affected by DMD.
-
Pittsburgh Shared context
DMD is based in Pittsburgh's hometown, establishing a shared locational context for the company's operations.
-
Albuquerque Shared context
DMD operates within the geographic context of Albuquerque, primarily focusing on road construction projects.
-
Jason Rhodes Transactional
Director Jason Rhodes executed a stock sale in DMD.
-
Samastipur Shared context
DMD is operating in Samastipur while managing flood relief efforts.
-
Brooklyn Mentioned together
Evidence provided relates to a third party and does not describe any interaction between DMD and Brooklyn.
History
Events by the month they beganNovember 2026
1 eventOctober 2026
2 eventsSeptember 2026
2 eventsShow 3 earlier months
August 2026
1 eventJuly 2026
3 events- Sarepta Therapeutics, which develops precision genetic medicines for DMD, trades on the Nasdaq and is headquartered in Cambridge.
- The FDA accepted the Biologics License Application (BLA) for a DMD therapy developed by a company led by John Cox.
- DMD develops therapeutics targeting muscle tissue through strategic collaborations involving Roche, Recursion, and Dyne Therapeutics.
June 2026
11 events- Director Jason Rhodes sold company stock of DMD, with the transaction disclosed in an SEC filing.
- Nippon Shinyaku is funding the development of treatments for DMD, with its US subsidiary located in New Jersey.
- DMD sponsors a fair dedicated to raising awareness about research in the field.
- Cumberland Pharmaceuticals is advancing clinical trials for DMD treatments in the US and internationally.
- Dyne announced the development of therapies for DMD and myotonic dystrophy type 1, with John Cox serving as CEO.
- Sarepta Therapeutics is developing gene therapies for DMD. The FDA has mandated a black box warning for ALF due to patient deaths linked to the compound in trials.
- FDA granted breakthrough therapy designation to Avidity Biosciences for a drug candidate targeting DMD.
- Wave Life Sciences delivered positive data from the N531 trial, with future milestones and payments remaining uncertain.
- Cumberland Pharmaceuticals' product Vibativ received regulatory approval in China.
- The FDA granted Orphan Drug Designation for KER-065, a therapeutic being developed by KROS for DMD.
- Wave Life Sciences, based in Singapore, is developing therapies for DMD and targeting Huntington’s disease.